[Pubmed] Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
Posté : 05 oct. 2023 12:00
J Neuroimmunol. 2023 Sep 28;384:578215. doi: 10.1016/j.jneuroim.2023.578215. Online ahead of print.
ABSTRACT
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).
PMID:37797472 | DOI:10.1016/j.jneuroim.2023.578215
Source: https://pubmed.ncbi.nlm.nih.gov/3779747 ... t6+86293ac